VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs
Launched by BACTIGUARD AB · Jan 24, 2020
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
The aim of the study is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard Infection Protection (BIP) coating.
VAP is likely to occur in 10-20% of patients who are ventilated for at least 48 hours. These patients face a mortality risk estimated to be twice as high compared with similar ICU patients without VAP. Furthermore, VAP results in an average excess length of ICU stay with high hospital cost.
Bactiguard has developed an endotracheal tube coated with a thin layer ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • intubation with a study tube and a presumed duration of ventilation for more than 24h,
- • age \> 18 y,
- • signed informed consent
- Exclusion Criteria:
- • tracheostomized patient
- • life expectancy less than 48h,
- • previous participation in the study
- • pregnant women.
About Bactiguard Ab
Bactiguard AB is a clinical trial sponsor dedicated to advancing innovative solutions in infection prevention and control. Based in Sweden, the company specializes in the development of medical devices coated with its proprietary Bactiguard technology, which effectively reduces the risk of catheter-associated infections. Bactiguard's commitment to enhancing patient safety is reflected in its rigorous research and development processes, aimed at delivering evidence-based solutions that improve health outcomes in various clinical settings. With a strong focus on collaboration and scientific excellence, Bactiguard AB plays a pivotal role in transforming healthcare practices globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liege, , Belgium
Liège, , Belgium
Patients applied
Trial Officials
Benoit Misset, MD,Prof.
Principal Investigator
CHU, Liege; Belgium
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials